Healthcare Industry News: influenza
News Release - August 20, 2007
Vical Names Andrew de Guttadauro Vice President, Corporate DevelopmentSAN DIEGO, Aug. 20 (HSMN NewsFeed) -- Vical Incorporated (Nasdaq: VICL ) today announced the enhancement of its management team with the appointment of Andrew R. de Guttadauro as Vice President, Corporate Development.
Prior to joining Vical, Mr. de Guttadauro was Senior Director of Strategy at Biogen Idec since February 2007, following a two-year assignment overseeing the commercial development of that company's Zevalin, the first radioimmunotherapy product approved for use in the United States. Before joining Biogen Idec, he spent the prior year at MedImmune, where he directed marketing efforts for the FluMist inhaled influenza vaccine. Mr. de Guttadauro served in various marketing positions of increasing responsibility at Amgen Inc. over a six-year period, with direct involvement in the marketing of Enbrel, Kineret, Aranesp, and Epogen products. He spent the first seven years of his career at Tap Pharmaceuticals, where he served in a series of sales and marketing positions, including contributions to the success of Prevacid and Lupron. Mr. de Guttadauro earned a bachelor of science degree in engineering from the United States Military Academy at West Point, followed by a three-year tour of duty as a Captain in the U.S. Army.
Vijay B. Samant, Vical's President and Chief Executive Officer, said, "We are very pleased to welcome Andrew to Vical's management team at this exciting time in the company's development. His proven leadership capabilities, solid project management skills, and breadth of experience in product sales and marketing, add another dimension to our current capabilities. As we advance with our independent product development programs, we look forward to applying Andrew's expertise in product commercialization, which includes hands-on contributions to the successful launch and market expansion of multiple products."
Vical researches and develops biopharmaceutical products based on its patented DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. Potential applications of the company's DNA delivery technology include DNA vaccines for infectious diseases or cancer, in which the expressed protein is an immunogen; cancer immunotherapeutics, in which the expressed protein is an immune system stimulant; and cardiovascular therapies, in which the expressed protein is an angiogenic growth factor. The company is developing certain infectious disease vaccines and cancer therapeutics internally. In addition, the company collaborates with major pharmaceutical companies and biotechnology companies that give it access to complementary technologies or greater resources. These strategic partnerships provide the company with mutually beneficial opportunities to expand its product pipeline and address significant unmet medical needs. Additional information on Vical is available at http://www.vical.com.
This press release contains forward-looking statements subject to risks and uncertainties that could cause actual results to differ materially from those projected. Forward-looking statements include statements about the company's focus, collaborative partners, product candidates, and developmental status. Risks and uncertainties include whether any product candidates will be shown to be safe and efficacious in clinical trials, the timing of clinical trials, whether Vical or its collaborative partners will seek or gain approval to market any product candidates, the dependence of the company on its collaborative partners, and additional risks set forth in the company's filings with the Securities and Exchange Commission. These forward-looking statements represent the company's judgment as of the date of this release. The company disclaims, however, any intent or obligation to update these forward-looking statements.
Source: Vical Inc
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.